Decoding Rheumatoid Arthritis Comorbidities: Molecular Mechanisms and Computational Advances

Rheumatoid arthritis (RA) is a chronic autoimmune disorder characterized by persistent systemic inflammation that extends far beyond the joints, giving rise to a wide range of comorbidities, including metabolic disorders, neurodegenerative conditions, osteoporosis, and various malignancies. These complications not only accelerate disease progression but also profoundly impair patient quality of life and overall survival. Understanding the molecular mechanisms that connect RA with its comorbidities is therefore essential for advancing risk prediction, enabling early diagnosis, and developing personalized therapeutic strategies. Traditional observational studies have provided valuable epidemiological evidence, yet they are frequently hampered by confounding variables and reverse causation. In recent years, rapid progress in computational methodologies has transformed RA research, offering more precise and unbiased approaches to dissect disease mechanisms. Large-scale retrospective analyses strengthen statistical associations, whereas bioinformatics pipelines and machine learning algorithms contribute to biomarker discovery, disease classification, and risk stratification. Mendelian Randomization has emerged as a powerful genetic tool for identifying causal relationships between RA and its comorbidities by employing genetic variants as instrumental variables. Furthermore, the integration of multi-omics layers-including genomics, transcriptomics, proteomics, and epigenomics-has greatly expanded insights into shared pathogenic pathways and unveiled promising therapeutic targets. Artificial intelligence-driven predictive models further enhance disease risk estimation and enable patient stratification based on molecular signatures, paving the way toward precision medicine in RA management. Collectively, this review highlights recent computational advances, underscoring their role in refining predictive models, elucidating mechanistic links between RA and comorbidities, and guiding the development of targeted therapeutic interventions to improve long-term patient outcomes.